3
Announcements
Trials
Browse
Landscape
Phase
Phase EARLY_PHASE1
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Recurrence
4
Multiple Myeloma
4
Lymphoma
4
Ovarian Neoplasms
3
Burkitt Lymphoma
3
Neoplasms, Plasma Cell
2
Nasopharyngeal Carcinoma
2
Lymphoma, T-Cell
2
Leukemia, Myeloid, Acute
2
Solid Tumors
1
Solid Tumor
1
Solid Cancer
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
1
POEMS Syndrome
1
Neuromyelitis Optica
1
Neuroblastoma
1
Neoplasms, Neuroepithelial
1
Neoplasms
1
Neoplasm, Residual
1
Neoplasm Metastasis
1
Myositis
1
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease
1
Myasthenia Gravis
1
Multiple Sclerosis
1
Metastatic Castration-resistant Prostate Cancer
1
Melanoma
1
Lymphoma, Mantle-Cell
1
Interventions
toripalimab
1
fludarabine
1
Cyclophosphamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase EARLY_PHASE1
×
Epstein-Barr Virus Infections
×
fludarabine
×
Clear all
NCT06224049
2024-03-12
GI-hNeoT-01
BGI, China
Phase EARLY_PHASE1
Recruiting
6 enrolled